Effects of lidoflazine on left ventricular function in patients

• Published in: Journal of cardiothoracic and vascular anesthesia 1997-02, Vol.11 (1), p.42-48
• Main Authors: De Hert, Stefan G., Rodrigus, Inez E., Haenen, Luc R., Ten Broecke, Pieter W., Boeckxstaens, Christianne J., Gillebert, Thierry C.
• Format: Article
• Language: English
• Subjects: Aged; Antianginal agents. Coronary vasodilator agents; Biological and medical sciences; Cardiovascular system; Coronary Artery Bypass; diastolic function; Double-Blind Method; Female; Hemodynamics; Humans; lidoflazine; Lidoflazine - pharmacology; Male; Medical sciences; Middle Aged; Pharmacology. Drug treatments; systolic function; Vasodilator Agents - pharmacology; Ventricular Function, Left - drug effects
• ISSN: 1053-0770; 1532-8422
• DOI: 10.1016/S1053-0770(97)90251-2

Objective : The present study evaluated the effects of the nucleoside transport inhibitor, lidoflazine, at a dose of 1 mg/kg, on left ventricular function. Design : Patients were randomly assigned to receive either lidoflazine or saline in a double-blind manner. Setting : A university hospital. Participants : The study was performed in 32 patients scheduled for elective coronary artery bypass surgery. Interventions : Left ventricular pressures were measured with fluid-filled catheters. Data were digitally recorded during pressure elevation induced by tilt-up of the legs. Transgastric short-axis echocardiographic views of the left ventricle were simultaneously recorded on videotape. Systolic function was evaluated with the slope (Ees, mmHg/mL) of the systolic pressure-volume relationship. Diastolic function was evaluated with the chamber stiffness constant (Kc, mmHg/mL) of the diastolic pressure-volume relationship. Cardiac function was essessed at baseline and after administration of either lidoflazine (group A [ n = 16]) or placebo (group B [ n = 16]). Data were compared using two-factor analysis of variance. Measurements and Main Results : At baseline, diastolic and systolic function were comparable in both groups. Lidoflazine increased Kc from 0.079 ± 0.015 to 0.125 ± 0.017 mmHg/mL and decreased Ees from 2.481 ± 0.213 to 1.217 ± 0.211 mmHg/mL ( p = 0.009 and p = 0.004, respectively). None of these changes occurred when placebo was administered. Conclusions : Administration of lidoflazine before the start of cardiopulmonary bypass impaired left ventricular systolic function but also increased diastolic stiffness.